What factors drive your selection between tafasitamab and epcoritamab for a patient with relapsed/refractory follicular lymphoma?

For an older patient or a patient with comorbidities, if one is prioritizing outpatient simplicity, tafasitamab + R² delivers an NCCN category 1 benefit with substantially lower acute immune toxicity. If CD19 CAR-T is the next planned therapy, however, the CD19-targeting overlap is a consideration t...

My decision is primarily based on efficacy, patient fitness, access to treatment, prior therapies, toxicity profile, and the patient's treatment goals.

ER2 has demonstrated very high response and CR rates with encouraging durability, making it a very attractive option for patients with relapsed FL w...

There are a number of factors to take into consideration when selecting therapy for a patient with relapsed/refractory follicular lymphoma. I consider factors related to the patient, factors related to the lymphoma, and factors related to treatment history. From the perspective of the patient, I tak...

There are clearly more infectious issues with epco with R2 vs taf R2. If someone has issues with recurrent infections, they may not choose. Also, for older patients, taf plus R2 may be given, as that may be the last regimen they need.